Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab combined with neoadjuvant chemotherapy for urothelial carcinoma
ChiCTR2000038426Phase 4Recruiting
- Sponsor
- 3 Qingchun Road East, Jianggan District, Hangzhou, Zhejiang, China
- Start
- Nov 2020
- Modality
- Small Molecules, PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of durvalumab, cisplatin and gemcitabine in transitional cell carcinoma (TCC), sponsored by 3 Qingchun Road East, Jianggan District, Hangzhou, Zhejiang, China. Primary endpoint: Objective response rate. Started Nov 2020; status: recruiting.
02
Drugs
durvalumabcisplatingemcitabine
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on ChiCTR2000038426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000038426.